Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage filings from Cardiff Oncology (CRDF) mix dense oncology science with complex regulatory detail. Whether you’re tracking financing rounds for onvansertib or reading the risk factors tied to PLK1 inhibition, finding the right data can be challenging. Investors regularly ask, “Where can I see Cardiff Oncology insider trading Form 4 transactions?” or “How does the latest Cardiff Oncology quarterly earnings report 10-Q filing affect cash runway?” We group those disclosures in one place and keep them updated the moment they hit EDGAR.
Stock Titan’s AI deciphers the text, turning hundreds of pages into concise insights. With real-time alerts, you’ll see Cardiff Oncology Form 4 insider transactions real-time, revenue trends from each Cardiff Oncology earnings report filing analysis, and the science discussed in every 8-K. Our platform offers:
- Cardiff Oncology SEC filings explained simply—plain-language notes beside each section.
- Cardiff Oncology annual report 10-K simplified with AI annotations linking clinical milestones to financial outcomes.
- Cardiff Oncology proxy statement executive compensation tables summarized so you can compare incentives to trial progress.
- Cardiff Oncology 8-K material events explained minutes after publication.
The result is a smoother research workflow. Need help understanding Cardiff Oncology SEC documents with AI? Use sentiment scores and key-phrase search to answer due-diligence questions fast. Prefer to monitor insider confidence? Our dashboard tracks every Cardiff Oncology executive stock transactions Form 4 alongside historical price moves. From liquidity analysis to pipeline catalysts, you’ll get the context you need without wading through jargon.
Cardiff Oncology (CRDF) filed an 8-K stating it issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2025. The press release was furnished as Exhibit 99.1.
The company’s common stock trades on The Nasdaq Stock Market under the symbol CRDF. The report was signed by Chief Executive Officer Mark Erlander on November 6, 2025.
Cardiff Oncology (CRDF) reported Q3 2025 results with royalty revenue of
Cash, cash equivalents and short-term investments totaled
In its lead mCRC program, Phase 2 CRDF-004 showed blinded independent central review ORR as of July 8, 2025: control 30%, onvansertib 20mg + SoC 42%, and onvansertib 30mg + SoC 49%. The combination was described as well-tolerated. Shares outstanding were 67,360,564 as of October 30, 2025.
Cardiff Oncology, Inc. (CRDF) received a joint Schedule 13G/A from Commodore Capital LP and Commodore Capital Master LP reporting zero beneficial ownership of the issuer's common stock (CUSIP 14147L108). The filing lists each filers jurisdiction (Delaware and Cayman Islands), business addresses, and certifies the securities were not acquired to influence control of the company. The cover pages show 0.00 shares and 0.0% of the class for both filers. The document includes a signed joint filing agreement and certifications by Michael Kramarz as Managing Partner and Authorized Signatory.
Cardiff Oncology, Inc. (CRDF) – Form 4 filing dated 06/30/2025
The filing discloses that director Rodney S. Markin received 40,565 stock options on 06/26/2025 at an exercise price of $3.16 per share. The options become exercisable on 06/26/2026 and expire on 06/26/2035. The transaction is coded “A,” indicating an award or grant with no cash paid by the insider. Following the grant, Markin holds 222,865 derivative securities (stock options) directly. No open-market purchases or sales of common stock were reported, and no changes were recorded in Markin’s non-derivative share ownership.
The grant is a routine equity incentive intended to align the director’s interests with those of shareholders. Given the modest size relative to Cardiff Oncology’s total shares outstanding, the transaction is considered immaterial from a dilution standpoint and does not, by itself, signal any change to the company’s strategic outlook or financial condition.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
